Meningitis Vaccine Switch C to ACWY and B

Written By Karen Dindial

Challenge

Epidemiological surveillance indicates an increase of serogroup MenY disease.

With the development of vaccines that protect against five types of meningitis strains that cause disease, the client requested DKI Health’s assistance to better understand adoption criteria for new vaccine formulations in seven countries to create a comprehensive vaccine development and switching strategy.

Our Solution

  • We systematically analyzed the national immunization programs (NIPs) and vaccine C policies in seven different countries, meticulously evaluating their decision-making frameworks regarding the adoption of novel vaccine formulations.

  • We identified the factors that posed challenges and those that facilitated the transition from C to ACW(135)Y vaccine. These insights were then juxtaposed with established commercial switching strategies aimed at fostering a well-coordinated approach to switching that integrated the unique policy landscapes of each respective country.

  • By actively engaging with our client, we strategically pinpointed zones where potential reputational risks might arise while also uncovering avenues of opportunity for effectively promoting the administration of the quadrivalent vaccine.

Benefit to Client

  • Comprehensive Vaccine Policy Insights: Provided a clear understanding of the mono and quadri-valent vaccine policy landscape.

  • Internal Strategy Facilitation: Supported internal alignment and approaches for executing feasible switch strategies.

  • Reputational Risk and Opportunity Identification: Identified areas of potential reputational risks and opportunities for supporting quadrivalent vaccination.

Karen Dindial
Previous

Antimicrobial Resistance (AMR)